Pfizer and its partner in developing a COVID-19 vaccine, BioNTech, announced the start of a global Phase 2/3 trial of the vaccine in roughly 4,000 pregnant women. The study will evaluate the vaccine’s safety, tolerability and immunogenicity in pregnant women and whether or not protective antibodies transfer to their infants. Prior animal studies, required by regulators, showed no evidence of fertility or reproductive toxicity associated with the vaccine. Rumors circulating through social media falsely claim COVID-19 vaccines are tied to infertility. (Pfizer news release, 2/18/21).
